Table 11.
Parameter | SOLE | FACE | Kwak (2015) |
---|---|---|---|
Study design | RCT | RCT | RWE |
Age (median) | LC: 60c LI: 60c |
L: 62c A:62c |
48.5a |
Post-menopausal (%) | LC: 77c LI: 76c |
L: 100 A: 100 |
51.5 |
T1 (%) | LC: 47c LI: 58c |
L: 47c,b A: 45.5c,b |
51.5 |
Stage 1 (%) | NR | 0 | 25.2 |
ER+ (%) | LC: 98c LI: 97.9c |
L: 98.4c A: 98.9c |
93.2 |
PR+ (%) | LC: 80c LI: 78c |
L: 79.8c A: 79.4c |
81.6 |
Abbreviations: A = anastrozole; ER = estrogen receptor; L = letrozole; LC = continuous letrozole; LI = intermittent letrozole; NR = not reported; PR = progesterone receptor; RCT = randomized controlled trial; RFS = recurrence-free survival; RWE = real-world evidence.
Mean age.
Includes T1 and T0 patients.
Full cohort (not exclusively HR+/HER2-).